The value of antimalarials in the treatment of lupus erythematosus has been well established since Page's article on the use of quinacrine (mepacrine).1 A recent article by Leeper and Allende2 compared the use of quinacrine, chloroquine, and amodiaquin for this condition and indicated that the latter two were preferable. Also, light-sensitivity eruptions have been successfully treated and recurrences prevented with quinacrine and chloroquine.3,4
Another antimalarial preparation under investigation is Plaquenil sulfate (7-chloro-4-[4-N-ethyl-N-β-hydroxyethylamino-1-methylbutylamino]-quinoline). This drug has also been referred to as Win 1258 and is a synthesized stable colorless crystalline solid. It is supplied in tablets of 0.2 and 0.4 gm. It is a 4-aminoquinoline, differing from chloroquine diphosphate in that one of the terminal ethyl groups on the tertiary amino nitrogen is replaced by a hydroxyethyl group.
Plaquenil sulfate has been mentioned by several investigators. Goldman5 felt it was ``certainly less toxic
BENNETT JH, REES RB. Plaquenil Sulfate in Treatment of Lupus Erythematosus and Light-Sensitivity Eruptions. AMA Arch Derm. 1957;75(2):181–183. doi:10.1001/archderm.1957.01550140025004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: